Abstracts tagged "Psoriatic arthritis"

Abstract Number: 422 • 2019 ACR/ARP Annual Meeting
The Impact of Adalimumab vs Placebo on Patient-Reported Outcomes and Utility Measures Among Patients with Moderately to Severely Active Psoriatic Arthritis
Vibeke Strand¹, Pankaj Patel ², Naijun Chen ² and Elizabeth M Lesser ³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago
Background/Purpose: Physical function and health-related quality of life (HRQoL) are negatively impacted in patients (pts) with PsA, and treatment with conventional and biological (b) DMARDs…
Abstract Number: 1012 • 2019 ACR/ARP Annual Meeting
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Yannick Degboe ¹, Flavia Sunzini ¹, Iain McInnes ² and Carl Goodyear¹, ¹University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: PsA is associated with bone erosion and inflammation-induced bone loss. This process is mediated by osteoclasts, and modulated by inflammatory cytokines (i.e. TNF, IL-1,…
Abstract Number: 1475 • 2019 ACR/ARP Annual Meeting
Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
Gustavo Citera¹, Emilce Schneeberger ², Peter Nash ³, Josef Smolen ⁴, Philip Mease ⁵, Enrique Soriano ⁶, Vesna Matulic ⁷, Claudia Helling ⁸, Annette Szumski ⁹, Rajiv Mundayat ¹⁰, Daniela Graham ¹¹ and Dario Ponce de Leon ¹², ¹Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³University of Queensland, Brisbane, Queensland, Australia, ⁴Medical University of Vienna, Vienna, Austria, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina, ⁷Pfizer Chile S.A., Santiago, Chile, ⁸Pfizer Inc, Buenos Aires, Argentina, ⁹Syneos Health, Princeton, NJ, ¹⁰Pfizer Inc, New York, NY, ¹¹Pfizer Inc, Groton, CT, ¹²Pfizer Inc, Lima, Peru
Background/Purpose: An international task force has agreed that remission or low disease activity (LDA) are key treatment targets for patients (pts) with PsA, and recommends…
Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Steven Feldman ¹, Jingchuan Zhang², Diane Martinez ³, Lorena Lopez-Gonzalez ³, Elizabeth Holt Marchlewicz ³, George Shrady ³, Alan Mendelsohn ⁴ and Yang zhao ⁵, ¹Wake Forest Baptist Health, Winston-Salem, NC, ²Sun Pharmaceutical Industries, Princeton, NJ, ³IBM Watson Health, Washington, DC, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Sun Pharmaceutical Industries, Princeton
Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
Abstract Number: 1857 • 2019 ACR/ARP Annual Meeting
High-resolution MRI Assessment of Flexor Tendon Pulleys in Psoriatic Arthritis for Disease Monitoring and Differentiation from Rheumatoid Arthritis Using a 16-channel Hand Coil
Philipp Sewerin¹, Daniel Benjamin Abrar ², Dennis McGonagle ³, Miriam Frenken ², Karl Ludgar Ratke ⁴, Stefan Vordenbaeumen ⁵, Ralph Brinks ⁶, Matthias Schneider ⁷, Benedikt Ostendorf ⁵ and Christoph Schleich ², ¹Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ²Institute for Diagnostic and Interventional Radiology, UKD, Heinrich Heine University, Duesseldorf, Germany, ³University of Leeds, Leeds, United Kingdom, ⁴Institute for Diagnostic and Interventional Radiology, UKD, Heinrich Heine University Düsseldorf, Duesseldorf, Germany, ⁵Policlinic and Hiller Research Unit of Rheumatology, UKD, Heinrich Heine University, Duesseldorf, Germany, ⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁷Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: To evaluate the value of 3 Tesla (T) magnetic resonance imaging (MRI) changes of flexor tendon pulleys for the differentiation of psoriatic (PsA) and…
Abstract Number: 2450 • 2019 ACR/ARP Annual Meeting
The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Rebecca Haberman¹, Samrachana Adhikari ¹, Deborah Ramirez ², Eileen Lydon ¹, Malavika Attur ¹, Andrea Neimann ¹, Soumya Reddy ¹, Andrea Troxel ¹ and Jose Scher ³, ¹NYU School of Medicine, New York City, ²NYU School of Medicine, New York, ³New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a heterogenous inflammatory disease affecting skin, joints, and other domains. While psychiatric diseases (i.e., depression and anxiety) are known comorbidities,…
Abstract Number: 2471 • 2019 ACR/ARP Annual Meeting
Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study
Erkan Kilic¹, Gamze Kilic ², Kemal Nas ³, Betul Sargin ⁴, Sevtap Acer Kasman ⁵, Hakan Alkan ⁶, Nilay Sahin ⁷, Gizem Cengiz ⁸, Nihan Cuzdan ⁹, Ilknur Albayrak Gezer ¹⁰, Dilek Keskin ¹¹, Cevriye Mulkoglu ¹², Hatice Resorlu ¹³, Ismihan Sunar ¹⁴, Ajda Bal ¹⁵, Mehmet Tuncay Duruoz ⁵, Okan Kucukakkas ¹⁶, Ozan Volkan Yurdakul ¹⁶, Meltem Alkan Melikoglu ¹⁷, Yildiray Aydin ³, Fikriye Figen Ayhan ¹⁸, Hatice Bodur ¹⁹, Mustafa Calis ⁸, Erhan Capkin ²⁰, Gul Devrimsel ²¹, Kevser Gök ²², Sami Hizmetli ²³, Ayhan Kamanli ³, Yasar Keskin ¹⁶, Hilal Kocabas ²⁴, Oznur Kutluk ²⁵, Nesrin Sen ²⁶, Omer Faruk Sendur ²⁷, Ibrahim Tekeoglu ³, Sena Tolu ²⁸, Murat Toprak ²⁹ and Tiraje Tuncer ²⁵, ¹Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, ²Karadeniz Technical University School of Medicine, Department of Physical Medicine and Rehabilitation, Trabzon, ³Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, ⁴Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, ⁵Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ⁶Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, ⁷Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, ⁸Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, ⁹Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, ¹⁰Selçuk University School of Medicine, PMR Department, Konya, Turkey, ¹¹Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, ¹²Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹³Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, ¹⁴Ankara Unversity School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Turkey, ¹⁵Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹⁶Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, ¹⁷Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, ¹⁸Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, ¹⁹Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, ²⁰Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, ²¹Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, ²²Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, ²³Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, ²⁴Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, ²⁵Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, ²⁶Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, ²⁷Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, ²⁸Medipol University School of Medicine, PMR Department, İstanbul, Turkey, ²⁹Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey
Background/Purpose: Psoriatic arthritis (PsA) has been defined as an inflammatory arthritis associated with psoriasis. The disease activity can be evaluated using many scales in patients…
Abstract Number: 2491 • 2019 ACR/ARP Annual Meeting
Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration
Lykke Midtbøll Ørnbjerg¹, Stylianos Georgiadis ², Lennart Jacobsson ³, Anne Gitte Loft ⁴, Florenzo Iannone ⁵, Burkhard Moeller ⁶, Joe Sexton ⁷, Herman Mann ⁸, Maria José Santos ⁹, Manuel Pombo-Suarez ¹⁰, Kari K. Eklund ¹¹, Matija Tomsic ¹², Bjorn Gudbjornsson ¹³, Şükran Erten ¹⁴, Catalin Codreanu ¹⁵, Irene van der Horst-Bruinsma ¹⁶, Johan Wallman ¹⁷, Marco Sebastiani ¹⁸, Michael J. Nissen ¹⁹, Eirik Kristianslund ²⁰, Karel Pavelka ⁸, Elsa Vieira-Sousa ²¹, Carlos Sánchez-Piedra ²², Nina Trokovic ²³, Ziga Rotar ²⁴, Thorvardur J Love ²⁵, servet Yolbas ²⁶, Ruxandra IONESCU ²⁷, Marleen van de Sande ¹⁶, Gareth Jones ²⁸, Brigitte Michelsen ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ¹, ¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ²DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ³Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁴Department of Rheumatology, Aarhus University Hospital., Aarhus, Denmark, ⁵Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ⁶University Hospital Bern, Bern, Switzerland, ⁷Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹¹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ¹²Department of Rheumatology, University Medical Centre, Ljubjana, Slovenia, ¹³Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹⁴Yıldırım Beyazıt University, Ankara, Turkey, ¹⁵Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁷Department of Clinical Sciences Lund, Rheumatology Lund University, Lund, Sweden, ¹⁸Rheumatology Unit, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine Relevance, Azienda Policlinico di Modena, University of Modena and Reggio Emilia, Modena, Italy, ¹⁹University Hospital Geneva, Geneva, Switzerland, ²⁰Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ²¹Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²³Helsinki University Central Hospital, Helsinki, Finland, ²⁴UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ²⁵Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²⁶TURKBIO registry and Celal Bayar University School of Medicin, Division of Rheumatology, Malatya, Turkey, ²⁷SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have contributed to improved prognosis in patients with psoriatic arthritis (PsA). However, many patients treated with TNFi fail to…
Abstract Number: 2514 • 2019 ACR/ARP Annual Meeting
Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Philip Helliwell¹, Andrew Bushmakin ², Dafna Gladman ³, Oliver FitzGerald ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Laura Coates ⁷, ¹University of Leeds, Leeds, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Toronto, Toronto, ON, Canada, ⁴University College Dublin, Dublin, Ireland, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
Abstract Number: 425 • 2019 ACR/ARP Annual Meeting
Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
Jörg Wendler ¹, Peter Wagener ², Schwarze Ilka ³, Evgenia Movshovich⁴, Nils Damann ⁴ and Frank Behrens ⁵, ¹Rheumatologische Schwerpunktpraxis, Erlangen, Germany, ²Fachpraxis für Rheumatologie und Osteologie, Bruchhausen-Vilsen, Germany, ³Praxis für Innere Medizin und Rheumatologie, Leipzig, Germany, ⁴Janssen-Cilag, Neuss, Germany, ⁵Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany
Background/Purpose: The wish of a treating physician is to make sure, that the patient gets an effective and safe therapy and is satisfied with the…
Abstract Number: 1079 • 2019 ACR/ARP Annual Meeting
Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018
M. Elaine Husni ¹, Brian Ung², Sven Richter ², Corey Pelletier ² and Marc Tian ², ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Celgene Corporation, Summit
Background/Purpose: Many new PsA treatments have emerged without clear guidelines on which therapy to use initially. We describe PsA treatment trends and patient journeys between…
Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
Abstract Number: 1524 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Alice Gottlieb ¹, Ana-Maria Orbai ², Rocco Ballerini ³, Richard C. Chou ⁴, Stephen Rozzo ³, Alan Mendelsohn³ and Luis R. Espinoza ⁵, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁵Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved by the FDA to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo-controlled, phase 2b…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 2451 • 2019 ACR/ARP Annual Meeting
Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Rebecca Persson¹, Katrina Wilcox Hagberg ¹, Ellen Qian ¹, Catherine Vasilakis-Scaramozza ¹, Steve Niemcryk ², Michael Peng ², Maria Paris ², Anders Lindholm ² and Susan Jick ³, ¹Boston Collaborative Drug Surveillance Program, Lexington, ²Celgene Corporation, Summit, ³Boston Collaborative Drug Surveillance Program and Boston University School of Public Health, Boston
Background/Purpose: Patients with psoriatic arthritis (PsA) are at increased risk for cardiovascular (CV) events, but different treatment options may not have the same rates of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].